Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...

Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...

Please provide your email address to receive an email when new articles are posted on . Impairment of social life was listed as an ongoing quality-of-life impact for every patient. Psychological and ...

Orca-T significantly improved survival free of moderate-to-severe cGvHD compared to alloHSCT, with rates of 78% versus 38%. Orca-T demonstrated a lower incidence of severe acute GvHD and non-relapse ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...

FDA approves Mesoblast's Ryoncil, the first U.S. MSC therapy, for children with steroid-refractory acute graft-versus-host disease. In a Phase 3 trial, 70% of SR-aGvHD patients responded to Ryoncil, ...

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...

Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cancers.

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer In REACH3 ...